THERAPY DOSSIER · th-ad0bf4a04829

Antibody-targeted anti-inducible nitric oxide synthase siRNA conjugated chitosan nanoparticles

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28482882 ↗2017Reported benefit

Targeted siRNA delivery reduces nitric oxide mediated cell death after spinal cord injury.

MouseSpinal cord injuryCompressionBALB/c in vivo; C57BL/6 bone marrow-derived macrophages in vitroFemaleIntraspinal injection into the injured cord via Hamilton syringe10 micrograms siRNA in 10 microlitres of chitosan nanoparti…Intraoperatively, after compression and before wound closure; exact interval no…

Model: Compression spinal cord injury: bilateral hemi-laminectomy at the low thoracic region with compression forceps deforming the cord to 0.15 mm, approximately 10 per cent of original cord width

Antibody-targeted siRNA chitosan nanoparticles reduced inducible nitric oxide synthase and Bax by approximately 50 per cent and roughly doubled Bcl-2 in the injured cord at 24 hours.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…